Adverum Clinical Site 254 — Edmond, Oklahoma

Adverum Clinical Site 254 is a clinical research site located in Edmond, Oklahoma, United States 73013.

Crixeo Clinical Trials Trust Score: 9/100 (FAILING). This profile has not yet been claimed by the site owner.

Adverum Clinical Site 254 has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD.

Sponsors: Adverum Biotechnologies, Inc..

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Edmond

Browse all research sites in Oklahoma · View every site in Edmond

• OK Clinical Research
• Research Site
• Retina Vitreous Center
• Tekton Research
• Clinical Investigations
• Conrad Clinical Research
• GSK Investigational Site
• Clinical Research Site
• Summit Medical Center
• Retina Vitreous Center, PLLC
• Tekton Research- Edmond
• Retina Vitreous Center in Edmond Oklahoma

Sponsor Feasibility Report

Trust Score: 9/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Adverum Clinical Site 254?

Adverum Clinical Site 254 has a Crixeo Trust Score of 9/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Adverum Clinical Site 254 conducted?

Adverum Clinical Site 254 has 1 clinical trials on record, with 1 currently active. Their work covers Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD.

Is Adverum Clinical Site 254 accredited by Crixeo Clinical Trials?

Adverum Clinical Site 254 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Adverum Clinical Site 254?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.